About Sanofi India Limited
Data last updated: 07 January 2026
Sanofi India Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Hoechst Gmbh (Holding Company). It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 May 1956, the company has been in operation for over 70 years.
Registered with ROC Mumbai under CIN L24239MH1956PLC009794. Listed on BSE: 500674 and NSE: SANOFI.
Capital: an authorised share capital of ₹23.5 Cr and a paid-up capital of ₹23.03 Cr. Formerly known as Hoechst Fedco Pharma P Ltd and Hoechst Fedco Pharma Ltd. It is led by directors including Deepak Arora and Renee Viswonath Amonkar.
Last AGM: 15 May 2025. Financial statements filed for year ended 31 December 2024. Office: Sanofi House Cts No.117 – B L&T Business Park Saki Vihar Road Powai, Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2023, the company reported a revenue of ₹2,916.4 Cr, a growth of 2.63% compared to the previous year.
The company has a workforce of approximately 2,191 employees as per the latest available data. It operates as a subsidiary of Hoechst Gmbh (Holding Company). Its group structure includes 1 subsidiary.
The company is associated with 2 brands - Allergy Free, Sanofi India. As per MCA filings, the company has open charges of ₹170.72 Cr and satisfied charges of ₹40.81 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sanofiindialtd.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressSanofi House Cts No.117 – B L&T Business Park Saki Vihar Road Powai, Mumbai, Maharashtra, India – 400072
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Sanofi India Limited
Sanofi India Limited has undergone 4 name changes throughout its history. The current legal name is Sanofi India Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Sanofi India Limited | Current |
| Hoechst Fedco Pharma P Ltd | Previous |
| Hoechst Fedco Pharma Ltd | Previous |
| Aventis Pharma Limited | Previous |
| Hoechst- Fedco Pharma Private Limited | Previous |
Associated Brands with Sanofi India Limited
Sanofi India Limited operates two associated brands: Allergy Free and Sanofi India. These brands represent Sanofi India Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Allergy education and management services in healthcare by Sanofi. | allergyfree.co.in | |
| Manufacturer of pharmaceutical products and vaccines | sanofiindialtd.com |
Business Activity of Sanofi India Limited
Sanofi India Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Sanofi India Limited
Sanofi India Limited is audited by Price Waterhouse & Co Chartered Accountants LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Price Waterhouse & Co Chartered Accountants LLP | blur-value | blur-value | blur-value |
Board of Directors of Sanofi India Limited
Sanofi India Limited is currently managed by 10 directors, with 47 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Deepak Arora | Managing Director | 27 Oct 2025 | 0 Years 8 Months | Current |
| Renee Viswonath Amonkar | Whole-Time Director | 26 Sep 2023 | 2 Years 9 Months | Current |
| Vaibhav Vinayak Karandikar | Director | 23 Feb 2021 | 5 Years 4 Months | Current |
| Rodolfo Hrosz | Director | 01 Jun 2022 | 4 Years 1 Months | Current |
|
Rachid Ayari
Also directs:
Apollo Sugar Clinics Limited
|
Whole-Time Director | 01 Dec 2023 | 2 Years 7 Months | Current |
| Usha Thorat | Director | 30 Apr 2016 | 10 Years 2 Months | Current |
Financials of Sanofi India Limited FY 2024 filings available
Sanofi India Limited reported revenue of ₹2,013.2 Cr (down 29.39% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2024 | FY 2023 |
|---|---|---|
| Revenue from Operations | ₹2,013.2 Cr | ₹2,851.1 Cr |
| Other Income | ₹16.5 Cr | ₹65.3 Cr |
| Total Income | ₹2,029.7 Cr | ₹2,916.4 Cr |
| Cost of Materials Consumed | ₹354.8 Cr | ₹564.4 Cr |
| Purchases of Stock-in-Trade | ₹564.3 Cr | ₹929 Cr |
| Changes in Inventories | ₹60.2 Cr | -₹292.4 Cr |
| Employee Benefit Expense | ₹240.2 Cr | ₹370.6 Cr |
| Finance Costs | ₹1.5 Cr | ₹1.7 Cr |
| Depreciation & Amortisation | ₹36.7 Cr | ₹39.6 Cr |
| Other Expenses | ₹302.9 Cr | ₹475.8 Cr |
| Total Expenses | ₹1,560.6 Cr | ₹2,088.7 Cr |
| Profit Before Exceptional Items & Tax | ₹469.1 Cr | ₹827.7 Cr |
| Exceptional Items | -₹37.7 Cr | ₹17.8 Cr |
| Profit Before Tax | ₹431.4 Cr | ₹845.5 Cr |
| Total Tax Expense | ₹117.7 Cr | ₹242.6 Cr |
| Net Profit | ₹413.3 Cr | ₹602.9 Cr |
| Other Comprehensive Income | ₹7.2 Cr | -₹1.3 Cr |
| Total Comprehensive Income | ₹420.5 Cr | ₹601.6 Cr |
| EBITDA (computed) | ₹507.3 Cr | ₹869 Cr |
| Basic EPS | ₹136.21 | ₹261.78 |
| Diluted EPS | ₹136.21 | ₹261.78 |
| Metrics | FY 2024 | FY 2023 |
|---|---|---|
| Total Assets | ₹1,611.8 Cr | ₹1,714.8 Cr |
| Non-current Assets | ₹347.5 Cr | ₹466.8 Cr |
| Current Assets | ₹1,264.3 Cr | ₹1,248 Cr |
| Property, Plant & Equipment | ₹255.8 Cr | ₹310 Cr |
| Inventories | ₹499.8 Cr | ₹663.8 Cr |
| Trade Receivables | ₹230 Cr | ₹131.7 Cr |
| Cash & Equivalents | ₹283.8 Cr | ₹394.5 Cr |
| Equity (Net Worth) | ₹860.6 Cr | ₹1,015.2 Cr |
| Equity Share Capital | ₹23 Cr | ₹23 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 |
| Current Liabilities | ₹719.2 Cr | ₹651.3 Cr |
| Total Liabilities | ₹751.2 Cr | ₹699.6 Cr |
| Metrics | FY 2024 | FY 2023 |
|---|---|---|
| Operating Cash Flow | ₹461.5 Cr | ₹230.4 Cr |
| Investing Cash Flow | -₹19.2 Cr | ₹37.5 Cr |
| Financing Cash Flow | -₹553 Cr | -₹878.3 Cr |
| Capital Expenditure | ₹36.4 Cr | ₹34.3 Cr |
| Free Cash Flow (computed) | ₹425.1 Cr | ₹196.1 Cr |
| Dividends Paid | ₹384.6 Cr | ₹868.3 Cr |
| Net Change in Cash | -₹110.7 Cr | -₹610.4 Cr |
| Metrics | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹514.9 Cr | ₹524 Cr | ₹463.5 Cr | ₹732.4 Cr | ₹693.9 Cr | ₹714.58 Cr | ₹706.1 Cr |
| Other Income | ₹5.9 Cr | ₹2.3 Cr | ₹4.8 Cr | ₹6.5 Cr | ₹12 Cr | ₹11.82 Cr | ₹15.7 Cr |
| Total Income | ₹520.8 Cr | ₹526.3 Cr | ₹468.3 Cr | ₹738.9 Cr | ₹705.9 Cr | ₹726.4 Cr | ₹721.8 Cr |
| Cost of Materials Consumed | ₹102.7 Cr | ₹93.1 Cr | ₹82.1 Cr | ₹143.7 Cr | ₹133.5 Cr | ₹130.99 Cr | ₹154.4 Cr |
| Purchases of Stock-in-Trade | ₹238.5 Cr | ₹201.8 Cr | ₹92.5 Cr | ₹40.8 Cr | ₹134.6 Cr | ₹395.22 Cr | ₹188.5 Cr |
| Changes in Inventories | -₹91.4 Cr | -₹34.93 Cr | ₹46.5 Cr | ₹123.9 Cr | ₹12.2 Cr | -₹226.43 Cr | -₹26.6 Cr |
| Employee Benefit Expense | ₹53.8 Cr | ₹56.7 Cr | ₹60.2 Cr | ₹92.4 Cr | ₹91.9 Cr | ₹93.13 Cr | ₹93.7 Cr |
| Finance Costs | ₹40 Lakh | ₹40 Lakh | ₹40 Lakh | ₹30 Lakh | ₹40 Lakh | ₹32.08 Lakh | ₹70 Lakh |
| Depreciation & Amortisation | ₹9.6 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr | ₹10.2 Cr | ₹9.88 Cr | ₹9.8 Cr |
| Other Expenses | ₹93 Cr | ₹87.64 Cr | ₹66.5 Cr | ₹112.7 Cr | ₹134.3 Cr | ₹113.41 Cr | ₹117.9 Cr |
| Total Expenses | ₹406.6 Cr | ₹413.71 Cr | ₹357.2 Cr | ₹523.8 Cr | ₹517.1 Cr | ₹516.52 Cr | ₹538.4 Cr |
| Profit Before Exceptional Items & Tax | ₹114.2 Cr | ₹112.59 Cr | ₹111.1 Cr | ₹215.1 Cr | ₹188.8 Cr | ₹209.88 Cr | ₹183.4 Cr |
| Exceptional Items | ₹8 Cr | ₹0 | -₹19 Cr | -₹26.7 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹122.2 Cr | ₹112.59 Cr | ₹92.1 Cr | ₹188.4 Cr | ₹188.8 Cr | ₹209.88 Cr | ₹183.4 Cr |
| Total Tax Expense | ₹30.9 Cr | ₹30.4 Cr | ₹23.9 Cr | ₹51.8 Cr | ₹51.1 Cr | ₹57.93 Cr | ₹60.5 Cr |
| Net Profit | ₹91.3 Cr | ₹82.19 Cr | ₹103.2 Cr | ₹136.6 Cr | ₹137.7 Cr | ₹151.95 Cr | ₹122.9 Cr |
| attributable to Owners | - | - | - | ₹0 | - | ₹0 | ₹0 |
| attributable to NCI | - | - | - | ₹0 | - | ₹0 | ₹0 |
| Other Comprehensive Income | ₹7.2 Cr | ₹0 | ₹0 | ₹0 | -₹1.3 Cr | ₹0 | ₹0 |
| Total Comprehensive Income | ₹98.5 Cr | ₹82.19 Cr | ₹103.2 Cr | ₹136.6 Cr | ₹136.4 Cr | ₹151.95 Cr | ₹122.9 Cr |
| EBITDA (computed) | ₹124.2 Cr | ₹121.99 Cr | ₹120.5 Cr | ₹225.4 Cr | ₹199.4 Cr | ₹220.08 Cr | ₹193.9 Cr |
| Basic EPS | ₹39.64 | ₹35.69 | ₹29.62 | ₹59.31 | ₹59.79 | ₹65.95 | ₹53.37 |
| Diluted EPS | ₹39.60 | ₹35.69 | ₹29.62 | ₹59.31 | ₹59.79 | ₹65.95 | ₹53.37 |
| Metrics | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹2,013.2 Cr | ₹2,851.1 Cr | ₹2,770.1 Cr | ₹2,956.6 Cr | ₹2,901.9 Cr |
| Other Income | ₹16.5 Cr | ₹65.3 Cr | ₹71.5 Cr | ₹74.4 Cr | ₹89.8 Cr |
| Total Income | ₹2,029.7 Cr | ₹2,916.4 Cr | ₹2,841.6 Cr | ₹3,031 Cr | ₹2,991.7 Cr |
| Cost of Materials Consumed | ₹354.8 Cr | ₹564.4 Cr | ₹549.7 Cr | ₹555.1 Cr | ₹591.4 Cr |
| Purchases of Stock-in-Trade | ₹564.3 Cr | ₹929 Cr | ₹651 Cr | ₹708.6 Cr | ₹604.7 Cr |
| Changes in Inventories | ₹60.2 Cr | -₹292.4 Cr | -₹11.1 Cr | ₹43.1 Cr | ₹57.5 Cr |
| Employee Benefit Expense | ₹240.2 Cr | ₹370.6 Cr | ₹405.9 Cr | ₹433.9 Cr | ₹460.8 Cr |
| Finance Costs | ₹1.5 Cr | ₹1.7 Cr | ₹1.7 Cr | ₹1.8 Cr | ₹1.8 Cr |
| Depreciation & Amortisation | ₹36.7 Cr | ₹39.6 Cr | ₹41.9 Cr | ₹66.7 Cr | ₹82.2 Cr |
| Other Expenses | ₹302.9 Cr | ₹475.5 Cr | ₹470.2 Cr | ₹453.4 Cr | ₹474.4 Cr |
| Total Expenses | ₹1,560.6 Cr | ₹2,088.4 Cr | ₹2,109.3 Cr | ₹2,262.6 Cr | ₹2,272.8 Cr |
| Profit Before Exceptional Items & Tax | ₹469.1 Cr | ₹828 Cr | ₹732.3 Cr | ₹768.4 Cr | ₹718.9 Cr |
| Exceptional Items | -₹37.7 Cr | ₹17.8 Cr | ₹132 Cr | ₹489.2 Cr | -₹41.7 Cr |
| Profit Before Tax | ₹431.4 Cr | ₹845.8 Cr | ₹864.3 Cr | ₹1,257.6 Cr | ₹677.2 Cr |
| Total Tax Expense | ₹117.7 Cr | ₹242.6 Cr | ₹243.7 Cr | ₹313.2 Cr | ₹199.6 Cr |
| Net Profit | ₹413.5 Cr | ₹603.2 Cr | ₹620.6 Cr | ₹944.4 Cr | ₹477.6 Cr |
| Other Comprehensive Income | ₹7.2 Cr | -₹1.3 Cr | ₹50 Lakh | -₹3.3 Cr | -₹8.8 Cr |
| Total Comprehensive Income | ₹420.7 Cr | ₹601.9 Cr | ₹621.1 Cr | ₹941.1 Cr | ₹468.8 Cr |
| EBITDA (computed) | ₹507.3 Cr | ₹869.3 Cr | ₹775.9 Cr | ₹836.9 Cr | ₹802.9 Cr |
| Basic EPS | ₹136.00 | ₹261.91 | ₹269.47 | ₹410.06 | ₹207.38 |
| Diluted EPS | ₹136.00 | ₹261.91 | ₹269.47 | ₹410.06 | ₹207.38 |
| Metrics | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Total Assets | ₹1,611.8 Cr | ₹1,715.1 Cr | ₹2,071.7 Cr |
| Non-current Assets | ₹347.6 Cr | ₹468.8 Cr | ₹461.4 Cr |
| Current Assets | ₹1,264.2 Cr | ₹1,246.3 Cr | ₹1,609.3 Cr |
| Property, Plant & Equipment | ₹311.3 Cr | ₹310 Cr | ₹305.2 Cr |
| Inventories | ₹499.8 Cr | ₹663.8 Cr | ₹408 Cr |
| Trade Receivables | ₹230 Cr | ₹131.7 Cr | ₹129.1 Cr |
| Cash & Equivalents | ₹283.8 Cr | ₹392.9 Cr | ₹1,004.9 Cr |
| Equity (Net Worth) | ₹860.6 Cr | ₹1,015.5 Cr | ₹1,275.8 Cr |
| Equity Share Capital | ₹23 Cr | ₹23 Cr | ₹23 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹719.2 Cr | ₹651.3 Cr | ₹739.7 Cr |
| Total Liabilities | ₹751.2 Cr | ₹699.6 Cr | ₹795.9 Cr |
| Metrics | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Cash Flow | ₹461.7 Cr | ₹230.8 Cr | ₹398.7 Cr | ₹558.8 Cr |
| Investing Cash Flow | -₹19.2 Cr | ₹35.5 Cr | ₹650.9 Cr | ₹630.8 Cr |
| Financing Cash Flow | -₹551.6 Cr | -₹878.3 Cr | -₹1,582.7 Cr | -₹849 Cr |
| Capital Expenditure | ₹36.4 Cr | ₹34.3 Cr | ₹22.2 Cr | ₹23 Cr |
| Free Cash Flow (computed) | ₹425.3 Cr | ₹196.5 Cr | ₹376.5 Cr | ₹535.8 Cr |
| Dividends Paid | ₹384.6 Cr | ₹868.3 Cr | ₹1,573 Cr | ₹840.6 Cr |
| Net Change in Cash | -₹109.1 Cr | -₹612 Cr | -₹533.1 Cr | ₹340.6 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹472.3 Cr | ₹419.8 Cr | ₹475.4 Cr | ₹406.3 Cr | ₹535.9 Cr | ₹514.9 Cr | ₹524 Cr | ₹463.5 Cr | ₹732.4 Cr | ₹693.9 Cr | ₹714.58 Cr | ₹706.1 Cr |
| Other Income | ₹4.4 Cr | ₹2.8 Cr | ₹4.9 Cr | ₹8.7 Cr | ₹3.3 Cr | ₹5.9 Cr | ₹2.3 Cr | ₹4.8 Cr | ₹6.5 Cr | ₹12 Cr | ₹11.82 Cr | ₹15.7 Cr |
| Total Income | ₹476.7 Cr | ₹422.6 Cr | ₹480.3 Cr | ₹415 Cr | ₹539.2 Cr | ₹520.8 Cr | ₹526.3 Cr | ₹468.3 Cr | ₹738.9 Cr | ₹705.9 Cr | ₹726.4 Cr | ₹721.8 Cr |
| Cost of Materials Consumed | ₹50.3 Cr | ₹55.3 Cr | ₹53.3 Cr | ₹62.1 Cr | ₹75.7 Cr | ₹102.7 Cr | ₹93.1 Cr | ₹82.1 Cr | ₹143.7 Cr | ₹133.5 Cr | ₹130.99 Cr | ₹154.4 Cr |
| Purchases of Stock-in-Trade | ₹148.2 Cr | ₹124.5 Cr | ₹269.8 Cr | ₹35.6 Cr | ₹84.1 Cr | ₹238.5 Cr | ₹201.8 Cr | ₹92.5 Cr | ₹40.8 Cr | ₹134.6 Cr | ₹395.22 Cr | ₹188.5 Cr |
| Changes in Inventories | ₹35.8 Cr | ₹28.3 Cr | -₹83.2 Cr | ₹111 Cr | ₹80.7 Cr | -₹91.4 Cr | -₹34.93 Cr | ₹46.5 Cr | ₹123.9 Cr | ₹12.2 Cr | -₹226.43 Cr | -₹26.6 Cr |
| Employee Benefit Expense | ₹42.8 Cr | ₹44.7 Cr | ₹41.9 Cr | ₹44.9 Cr | ₹53.8 Cr | ₹53.8 Cr | ₹56.7 Cr | ₹60.2 Cr | ₹92.4 Cr | ₹91.9 Cr | ₹93.23 Cr | ₹93.7 Cr |
| Finance Costs | ₹30 Lakh | ₹60 Lakh | ₹40 Lakh | ₹40 Lakh | ₹30 Lakh | ₹40 Lakh | ₹40 Lakh | ₹40 Lakh | ₹30 Lakh | ₹40 Lakh | ₹32.08 Lakh | ₹70 Lakh |
| Depreciation & Amortisation | ₹9 Cr | ₹9.5 Cr | ₹9.1 Cr | ₹9.1 Cr | ₹9.6 Cr | ₹9.6 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr | ₹10.2 Cr | ₹9.88 Cr | ₹9.8 Cr |
| Other Expenses | ₹52.4 Cr | ₹76.7 Cr | ₹59.4 Cr | ₹57.8 Cr | ₹69.7 Cr | ₹93 Cr | ₹87.64 Cr | ₹66.5 Cr | ₹112.7 Cr | ₹134.3 Cr | ₹113.12 Cr | ₹117.9 Cr |
| Total Expenses | ₹338.8 Cr | ₹339.6 Cr | ₹350.7 Cr | ₹320.9 Cr | ₹373.9 Cr | ₹406.6 Cr | ₹413.71 Cr | ₹357.2 Cr | ₹523.8 Cr | ₹517.1 Cr | ₹516.33 Cr | ₹538.4 Cr |
| Profit Before Exceptional Items & Tax | ₹137.9 Cr | ₹83 Cr | ₹129.6 Cr | ₹94.1 Cr | ₹165.3 Cr | ₹114.2 Cr | ₹112.59 Cr | ₹111.1 Cr | ₹215.1 Cr | ₹188.8 Cr | ₹210.07 Cr | ₹183.4 Cr |
| Exceptional Items | ₹0 | ₹0 | -₹27.3 Cr | ₹0 | ₹0 | ₹8 Cr | ₹0 | -₹19 Cr | -₹26.7 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹137.9 Cr | ₹83 Cr | ₹102.3 Cr | ₹94.1 Cr | ₹165.3 Cr | ₹122.2 Cr | ₹112.59 Cr | ₹92.1 Cr | ₹188.4 Cr | ₹188.8 Cr | ₹210.07 Cr | ₹183.4 Cr |
| Total Tax Expense | ₹35.3 Cr | ₹21.3 Cr | ₹26.3 Cr | ₹24.6 Cr | ₹45.8 Cr | ₹30.9 Cr | ₹30.4 Cr | ₹23.9 Cr | ₹51.8 Cr | ₹51.1 Cr | ₹57.93 Cr | ₹60.5 Cr |
| Net Profit | ₹102.6 Cr | ₹61.7 Cr | ₹76 Cr | ₹69.5 Cr | ₹119.5 Cr | ₹91.3 Cr | ₹82.19 Cr | ₹103.4 Cr | ₹136.6 Cr | ₹137.7 Cr | ₹152.14 Cr | ₹122.9 Cr |
| Other Comprehensive Income | ₹0 | ₹1.7 Cr | ₹0 | ₹0 | ₹0 | ₹7.2 Cr | ₹0 | ₹0 | ₹0 | -₹1.3 Cr | ₹0 | ₹0 |
| Total Comprehensive Income | ₹102.6 Cr | ₹63.4 Cr | ₹76 Cr | ₹69.5 Cr | ₹119.5 Cr | ₹98.5 Cr | ₹82.19 Cr | ₹103.4 Cr | ₹136.6 Cr | ₹136.4 Cr | ₹152.14 Cr | ₹122.9 Cr |
| EBITDA (computed) | ₹147.2 Cr | ₹93.1 Cr | ₹139.1 Cr | ₹103.6 Cr | ₹175.2 Cr | ₹124.2 Cr | ₹121.99 Cr | ₹120.5 Cr | ₹225.4 Cr | ₹199.4 Cr | ₹220.27 Cr | ₹193.9 Cr |
| Basic EPS | ₹44.55 | ₹26.79 | ₹32.99 | ₹30.18 | ₹51.89 | ₹40.00 | ₹35.69 | ₹29.62 | ₹59.31 | ₹59.79 | ₹66.08 | ₹53.37 |
| Diluted EPS | ₹44.55 | ₹26.79 | ₹32.99 | ₹30.18 | ₹51.89 | ₹40.00 | ₹35.69 | ₹29.62 | ₹59.31 | ₹59.79 | ₹66.08 | ₹53.37 |
Shareholding Pattern of Sanofi India Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 60.40%, foreign institutional investors hold 5.64%, domestic institutional investors hold 21.13%, retail and other public shareholders hold 12.83% of Sanofi India Limited. The company had 75,758 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| Public | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| Public | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% | 39.60% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | - |
Board & Governance of Sanofi India Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sanofi India Limited has 10 directors - 3 independent and 4 executive. The board is chaired by Aditya Narayan.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Aditya Narayan | Non-Executive - Independent Director · Chairperson | 2016-04-30 | 1 |
| Usha Thorat | Non-Executive - Independent Director | 2016-04-30 | 1 |
| Rahul Bhatnagar | Non-Executive - Independent Director | 2020-07-29 | 5 |
| Sudipta Chakraborty | Executive Director | 2026-03-01 | 1 |
| Vaibhav Karandikar | Non-Executive - Non Independent Director | 2023-12-01 | 1 |
| Rachid Ayari | Executive Director | 2023-12-01 | 1 |
| Eric Mansion | Non-Executive - Non Independent Director | 2024-06-03 | 1 |
| Mahadev Gawade | Executive Director | 2025-08-11 | 1 |
| Deepak Arora | Executive Director · MD | 2025-10-27 | 1 |
| Rodolfo Hrosz | Non-Executive - Non Independent Director | 2025-05-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Rahul Bhatnagar (Chairperson), Usha Thorat, Vaibhav Karandikar |
| Nomination and remuneration committee | Usha Thorat (Chairperson), Rahul Bhatnagar, Eric Mansion |
| Stakeholders Relationship Committee | Usha Thorat (Chairperson), Deepak Arora, Rachid Ayari |
| Risk Management Committee | Usha Thorat (Chairperson), Rahul Bhatnagar, Rachid Ayari, Mahadev Gawade, Deepak Arora |
| Corporate Social Responsibility Committee | Usha Thorat (Chairperson), Rahul Bhatnagar, Deepak Arora |
Group Structure of Sanofi India Limited
Sanofi India Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Sanofi India Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Sanofi Consumer Healthcare India Limited | U21002MH2023PLC402652 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Sanofi India Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Sep 2001 | Hdfc Limited | ₹19.75 Cr | Open |
| 25 Oct 1993 | Icici Limited | ₹5 Cr | Open |
| 31 Dec 1992 | State Bank of India | ₹40 Cr | Open |
| 03 Dec 1992 | State Bank of India | ₹40 Cr | Open |
| 11 Sep 1992 | State Bank of India | ₹3.2 Cr | Open |
Total charge records: 41 View all charges
Employees and EPFO Compliance at Sanofi India Limited
Sanofi India Limited has a workforce of 2,191 employees as of Jul 30, 2024.
Employee Count & EPFO Data of Sanofi India Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sanofi India Limited
GSTIN & GST Filing Data of Sanofi India Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sanofi India Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Sanofi India Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sanofi India Limited
MSME Payment Delays by Sanofi India Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sanofi India Limited
Subsidiaries & Group Companies of Sanofi India Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sanofi India Limited with ownership details.
MCA Filings & Documents of Sanofi India Limited
MCA Filings & Documents of Sanofi India Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sanofi India Limited
Recent News on Sanofi India Limited
Frequently Asked Questions about Sanofi India Limited
Sanofi India Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 02 May 1956 (70+ years old) and is registered under CIN L24239MH1956PLC009794. Listed on BSE: 500674 and NSE: SANOFI. The company has 2,191 employees.
Sanofi India Limited reported revenue of ₹2,916.4 Cr for FY 2023 (up 2.63% YoY).
The current directors of Sanofi India Limited are:
The primary industry of Sanofi India Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Sanofi India Limited is listed on both BSE (code: 500674) and NSE (symbol: SANOFI).
Sanofi India Limited can be reached at the registered office: Sanofi House Cts No.117 – B L&T Business Park Saki Vihar Road Powai, Mumbai, Maharashtra, India – 400072, or through the website sanofiindialtd.com.